AusperBio Raises $73M in Series B Financing to Develop AHB-137 for Chronic Hepatitis B
Shots:
- Following Series A round in Jul 2024, AusperBio has raised $73M in Series B financing led by HanKang Capital, with support from Sherpa Capital, CDH Investments and others
- The funding will support P-II development (both China & global) of AHB-137, advance commercial-scale manufacturing as well as expand therapeutic pipeline & operational capabilities
- AHB-137, an innovative antisense oligonucleotide (ASO) from AusperBio's Med-Oligo platform, is being developed to treat chronic hepatitis B. It has completed a global P-Ib trial and is under various P-II studies across China, progressing toward an HBV cure
Ref: PR Newswire | Image: AusperBio
Related News:- The NMPA Grants Breakthrough Therapy Designation to AusperBio’s AHB-137 for Treating Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
